Welcome! We look forward to meeting you and discuss how iPSC technology can support your projects.
Ncardia is a leader in contract research, development and manufacture of iPSC-based solutions for early and preclinical drug discovery. Our goal is to enable pharmaceutical and therapeutics companies to make more confident decisions in discovery and development by integrating iPSC technologies into their screening processes.
With more than 10 years of iPSC experience, the scientific team at Ncardia has the required expertise to generate iPSC-derived cells in a time-effective and reproducible manner and to model a range of neurodegenerative diseases. Our large-scale manufacturing capabilities enable batch-to-batch reproducibility and allow for high-throughput screening of large libraries. Moreover, Ncardia has the capabilities to develop and optimize assays to evaluate a wide range of neurodegeneration-associated phenotypes. Selection of the most relevant readouts is ensured to enable screening of any therapeutic modality.